















































Characteristic	Adjusted OR (95% CI) ^a	P Value ^b	Adjusted OR (95% CI) ^c	P Value
UVB exposure (1 SD increase)	0.72 (0.56-0.93)	.01	0.75 (0.58-0.97)	.03
Years of education, median		.001	CONTRACTOR OF THE	<.001
First tertile (7)	1 [Reference]	NA	1 [Reference]	NA
Second tertile (10)	1.26 (0.99-1.58)	.06	1.22 (0.96-1.57)	.10
Third tertile (14)	2.08 (1.41-3.06)	.001	2.04 (1.40-2.96)	.001
25(OH)D ₃ concentrations (continuous)	0.99 (0.98-1.00)	.48	NA	NA
Quintiles of 25(OH)D _{3,} median, nmol/L		.31		.31
First quintile (19.9)	1 [Reference]	NA	1 [Reference]	NA
Second quintile (33.1)	0.96 (0.79-1.31)	.78	0.95 (0.74-1.22)	.77
Third quintile (45.3)	0.87 (0.64-1.38)	.55	0.89 (0.59-1.36)	.62
Fourth quintile (58.9)	0.75 (0.47-1.20)	.24	0.78 (0.51-1.20)	.28
Fifth quintile (77.0)	0.87 (0.51-1.47)	.60	0.87 (0.56-1.38)	.59
Quintiles of plasma lutein, median, µmol/L		<.001		<.001
First quintile (0.03)	1 [Reference]	NA	1 [Reference]	NA
Second quintile (0.05)	0.93 (0.80-1.08)	.34	0.94 (0.81-1.10)	.48
Third quintile (0.11)	0.82 (0.55-1.20)	.30	0.83 (0.55-1.25)	.39
Fourth quintile (0.22)	0.89 (0.62-1.27)	.51	0.87 (0.63-1.19)	.41
Fifth quintile (0.48)	0.57 (0.46-0.72)	.001	0.59 (0.48-0.73)	<.001

















Sydney Adolescent Vascular and Eye Study

Most Myopic < 14 hours / week outdoors & > 25.5 hours / week of near work

Least Myopic High time outdoors & < 17.5 hours / week of near work

> Near work time > time outdoors Baseline 2.69 greater odds of myopia

Follow-Up 1.95 greater odds of myopia

Time outdoors reduces the incidence of myopia onset but the evidence is unclear if it slows the rate of myopia progression.







Why does percentage slowing matter?

Reducing the rate of myopia progression by

- ▶ 33% would lead to a reduction of 73% in the freq of high myopia
- $\triangleright~50\%$ would lead to a reduction of 90% in the freq of high myopia

High myopia (> 5 D) is accompanied by an increased risk

- Choroidal neovascularization (CNV)
- Retinal detachment

Brennan N. Predicted reduction in high myopia for various degrees of myopia control. Contact Lens & Anterior Eye. Dec 2012 Vol 35, Suppl I, p e14-e15.

- Glaucoma
- Cataract



Туре	Odds Ratio [95% confidence interval]
Nuclear	2.81 [1.94-4.06]
Cortical	1.08 [0.90-1.30]
Posterior subcapsular	1.93 [1.49-2.49]
stematic review of 12 popi	ulation-based studies
8,007 subjects aged 30-97	
,007 subjects aged 30-97	

Optic Disc Features in Highly Myopic Eyes: The ZOC-BHVI High Myopia Cohort Study

Zhixi Li, MD,¹ Xinxing Guo, MD, PhD,^{1,2} Ou Xiao, MD,¹ Pei Ying Lee, BOptom,³ Ran Liu, MD,¹ Decai Wang, MD, PhD,¹ Padmaja Sankaridurg, PhD,⁴ and Mingguang He, MD, PhD^{1,3*}

- ▶ -9.36 ± 3.46 D
- Axial length: 27.51 ± 1.63 mm
- Optic disc
 - Tilt: 81.2%
 - Rotation: 48.3%
- β-zone PPA: 92.8%





	Myop	Jia	
Variable	High (≤ -6.00 D)	Mild to Moderate (> -6.00 D)	p
Number (%) of eyes	231 (55)	189 (45)	1
Age (Years)	36.55 (21-55)	32.74 (21-59)	<0.001
Sph Equ (D)	-8.19 (-14.88, -6.00)	-4.58 (-5.88, -2.38)	
Axial length (mm)	26.74 (24.35-30.91)	25.41 (23.45-27.28)	<0.001
IOP (mm Hg)	13.31 (9-21)	12.53 (8-18)	<0.001
Average RNFL (µm)	87.82 (65.0-110.5)	91.74 (65.0-112.0)	<0.001
Vertical CDR	0.38 (0.06-0.83)	0.40 (0.06-0.75)	0.207
CCT (µm)	553.71 (490-656)	555.17 (471-663)	0.634
	Biswas glaucoi refract Poster	et al. Prevalence and risk factors o ma in myopic subjects attending a c ive surgery clinic in Hong Kong.AR ; 2014.	if :orneal IVO

RNFL Thickness	Group I Mean±SD (µm)	Group II Mean±SD (µm)	95% CI (µm)	p-value
Average	87.89±10.37	111.64±12.6	-28.59 to -18.91	=0.00001
Temporal	70.06±14.13	81.30 ±10.51	-16.57 to -05.90	=0.000068
Superior	109.47±19.83	137 ±23.64	-36.63 to -18.42	=0.00001
Nasal	67.06±17.37	86.80 ±14.95	-26.63 to -12.85	=0.00001
Inferior	104.74±14.05	141.5±19.63	-43.81 to -29.68	=0.00001









Myopic Macular Degeneration

- Shihpai, Taiwan
- Population-based cross-sectional study
- > 2,045 elderly Chinese 65 years of age or older
- Cause of visual impairment
- Cataract: 41.7%
- Myopic macular degeneration: 12.5%
- Age-related macular degeneration: 10.4%

Hsu et al. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004 Jan;111(1):62-9.



Vonghanit et al.	OR	CI	(95%)	
		(lower)	(upper)	
-1.0 to -2.99D	2.2	0.47	9.9	
-3.0 to -4.99D	9.7	2.63	35.8	
-5.0 to -6.99D	40.6	13.27	124.4	_
-7.0 to -8.99D	126.8	34.02	472.3	
<=-9.0D	348.6	121.05	1003.9	
Any Myopia	18			•
			-	
			0.1	1.0 3.0 10.0 30.0 100.0 500.0
				Odds Ratio
Vongphanit J, Mithcell P,W progression of myopic ret	ang JJ. Prevale	ence and older popu	ulation.	
Uphthalmology 2002 Apr	;109(4):704-1	1.		



Characteristics	Total Cohort	High Myopia without Pathologic Myopia Cohort	Pathologic Myopia Cohort
No. of eyes (%)	810	289 (35.7%)	521 (64.3%)
Age, yrs			\sim
Mean \pm SD	42.3±16.8	32.4±16.5	47.7±14.2
Range	3-85	3-85	7-76
Axial length, mm			
Mean \pm SD	28.8±1.9	27.6±1.4	29.4±1.8
Range	24.2-34.3	24.2-31.1	25.1-34.3
3CVA, logMAR			
Mean \pm SD	0.26±0.41	0.03±0.19	0.39±0.44
Range	-0.18 to 2.00	-0.18 to 1.00	-0.18 to 2.00
Modified myopic maculopathy according to META-PM study, no. (%) [†]			
Category 0 (no maculopathy)	22 (2.7)	22 (7.7)	
Category 1 (tessellated fundus)	277 (34.2)	267 (92.4)	10 (1.9)
Category 2 (diffuse atrophy)	361 (44.6)		361 (69.3)
Category 3 (patchy atrophy)	115 (14.2)		115 (22.1)
Category 4 (macular atrophy)	35 (4.3)		35 (6.7)
Myopic CNV	140 (17.3)		140 (26.9)
(including CNV-related macular atrophy)			
Lacquer cracks	116 (14.3)		116 (22.2)





Table 2. Risk of N and Spherical Ec	/isual Impairment by Axial Le quivalent Category by Age	ength
	OR (95% CI)	
Category	<60 y	≥60 y
Axial length, mm	1	
<24	1 [Reference]	1 [Reference]
24 to <26	0.95 (0.51 to 1.80)	0.65 (0.29 to 1.48)
26 to <28	2.01 (0.88 to 4.62)	3.07 (1.26 to 7.49)
28 to <30	11.01 (5.23 to 23.20)	9.69 (3.06 to 30.71)
≥30	24.69 (11.02 to 55.31)	93.62 (38.35 to 228.55)
Spherical equivalent, D		
>-0.5	1 [Reference]	1 [Reference]
-0.5 to >-3	0.69 (0.34 to 1.43)	0.92 (0.62 to 1.35)
-3 to >-6	1.42 (0.66 to 3.05)	1.71 (1.07 to 2.74)
-6 to >-10	2.95 (1.35 to 6.42)	5.54 (3.12 to 9.85)
-10 to >-15	6.79 (2.87 to 16.06)	7.77 (3.36 to 17.99)
<=15	27.85 (11.34 to 68.37)	87.63 (34.50 to 222.58)



Better Candidates for LASIK

- Only 17% of patients that get LASIK were referred by their optometrist
- Minimal central corneal thickness for a -6.00 ablation is 496 microns
- Conservative 300 micron stromal bed
- 100 micron flap thickness (Intralase 150 kHz, Ziemer Z4, or WaveLight FS200)
- 96 microns (16 microns per diopter)







Baseline -4.12 s	ph, -0.62 cy	 1 autol to anth	
in each year Year/myopia (D)	OK lens ⁴	Atropine ⁵	Lin et al. Overnight orthokeratology is comparabl
1	0.29±0.31	0.31 ± 0.19	with atropine in controlling
2	0.27 ± 0.24	0.35 ± 0.25	2014 Mar 21,14,40
3	0.28 ± 0.31	0.32 ± 0.23	2014 11al 31,14.40.
Year/astigmatism (D)	OK"	Atropine ⁵	
1	±0.08±0.11	±0.03 ± 0.02	
2	$\pm 0.08 \pm 0.42$	$\pm 0.09 \pm 0.12$	
3	±0.12 ± 0.35	±0.11 ± 0.16	
Year/axial length (mm)	OK lens*	Atropine ⁵	
1	0.28 ± 0.08	0.38 ± 0.09	
2	0.30 ± 0.09	0.37 ± 0.12	
3	0.27 ± 0.10	0.36 ± 0.08	

 Low-concenti 438 children Age 4 to 12 y I gtt OU QH 	ration Atropine for № years IS x I year	1yopia Progression
Atropine concentration	Mean SE change	Axial length increase
0.05%	-0.27 ± 0.61	0.20 ± 0.25 mm
0.025%	-0.46 ± 0.45	0.29 ± 0.20 mm
0.01%	-0.59 ± 0.61	0.36 ± 0.29 mm

Atropine concentration	Mean SE change Diopters / month	Axial length increase
0.05%	-0.019	0.019 mm
0.025%	-0.047	0.025 mm
0.01%	-0.07	0.037 mm
Before atropine	-0.134	0.046 mm
 285 children 6.8% of the 0.05% NPA > 10 D in a 	% atropine group still prog Il three atropine groups	ressed 0.5 to 1 D / year

	Family history	/ increases	odds	of myopia	by	8.155	times	[3.6 to	18.3]
--	----------------	-------------	------	-----------	----	-------	-------	---------	-------

Moon JS, Shin SY. The diluted atropine inhibition of myopia progression in Korean children. Int J Ophthalmol. 2018 Oct 18;11(10):1657-1662.

	AT	OM2 stu Chia et al 201	idy 2		AMP stud Yam et al 2018	У
Atropine dosage:	0.5%	0.1%	0.01%	0.01%	0.025%	0.05%
Mydriasis (mm)	+3	+3	+1	+0.5	+0.8	+1
Amps baseline (D)	15.8	16.7	16.2			
Amps 2 weeks	2.2	3.8	11.3	1 year amps reduction		
Amps 2 years	4.0	6.8	11.8	-0.3D	-2D	-1.6D
Refractive efficacy (%)	75	68	59	27	43	66
Axial efficacy (%)	29	25	-8	12	29	51







	< Q atropine	ß
Atropi	Atropine 1 eye dropper (5ml) 1%	
7 Y	♥ Los Angeles, CA	
	CVS Pharmacy § 2.4 miles	COUPON \$24.75
	Target (CVS) § 2.9 miles	COUPON \$24.75
	Walgreens	COUPON \$28.10
	Community, a Walgreens Pharmacy 9 2.0 miles	COUPON \$28.10
	Ralphs	COUPON \$49.97
•	Rite Aid 9 2.1 miles	COUPON \$56.90



	Actual Study Start Date 1 : November 20, 2017
	Estimated Primary Completion Date 0 : November 2021
	Estimated Study Completion Date 1 : November 2022
•	Multicenter randomized trial (FDA)
Þ	3 treatment arms (placebo, 0.01%, 0.02% atropine at 2:2:3 ratio)
	Instillation of drops every night; single use, preservative free vials
•	4-year study: 2 stages (efficacy for 3 years, cross over for last year)
Þ	Baseline and 6-month visits
	3-month visits (provide study drug; compliance check - short visit)
Þ	No cost for drops or examination visits
•	Study visit compensation provided to family (\$50/visit & \$5 gift card to child) and \$200/year toward optical
	•



Orthokeratology	apleton et al.The incidence of contact lens- ated microbial keratitis in Australia. phthalmology. 2008 Oct;115(10): 1655-62.
Microbial Keratitis	in 10,000
Glasses	1
Corneal GPs	1.2
SCL (hydrogel) daily wear	1.9-4.2
 SCL (silicone hydrogel) daily w 	ear II.9
 SCL (hydrogel) extended wear 	19.5
 SCL (silicone hydrogel) extend 	ed wear 25.4
 National Taiwan University H 10 cases in 15 months Chang Gung Memorial Hospi 68 cases in 4 years 	ospital tal

Orthokeratology	related microb Ophthalmolog	ial keratit y. 2008 O	is in Australia. ct;115(10):1655-6
Microbial Keratitis		i	in 10,000
 Orthokeratology 		7.7	[0.9-27.8]
 Ortho-k (kids) 		13.9	[1.7-50.4]
Ortho-k (adults)		0.0	[0.0-31.7]
 SCL (silicone hydrogel) d 	aily wear	11.9	
SCL (hydrogel) extended	wear	19.5	
 SCL (silicone hydrogel) e 	xtended wear	25.4	
Bullimore et al. The Risk of Mici With Overnight Corneal Resha Optom Vis Sci. 2013 Sep;90(9):9	robial Keratitis ping Lenses. 337-44.		











In ortho-k, how much peripheral plus / myopic defocus are we creating?















































Proclear	MATERIAL/H2O CONTENT	omafilcon B / 62%
PC Individge" CooperVision'	BASE CURVE (Mm)	8.8
Carlo La	DIA(Mm)	14.4
Carl Call Cold	SPHERE POWER	+20.00D to -20.00D (0.50 steps after +/-6.50D
	CYLINDER POWER	-0.75 to -5.75 (0.50 steps)
	AXIS	5 ⁰ to 180 ⁰ (5 ⁰ steps)
	ADD POWER	+1.00 to +4.00 (0.50 steps
	DESIGN	D lens / N lens
	WEARING SCHEDULE	Daily
	Dk/T (At -3.00D)	48.6
	REVENUE CARTON SIZE	6-pack blisters
	REPLACEMENT SCHEDULE	Monthly











Custom Stable Aurora

The back surface of the CS Aurora is that of the CS Elite (toric the fitting principals listed under the CS Elite section. Over-re Simply r Stable fit



The CS Aurora is available with center zones of 1.0mm-3.5mm. Fitting sets contain options of distance and near in standard zone sizes of 1.5 (Clear), 2.0 (Green) and 2.5 (Blue).

6.0 mm intermediate add zone on both eyes. This gives progressive add power on the distance lens and our progressive "reverse add" on the near lens.

Add power is available +1.00 to +3.50





annoying; adaptation

-4.75-1.00x010

-4.50-0.75×180

-5.00-0.75×180

-5.00-0.75×180

-6.25-1.00×180

-6.50-0.75×180

-5.75-0.25×180 -5.50-0.75×180

Ortho-k attempted

Naturalvue MF I-day

Atropine 0.05%

- 75% first fit success rate

3/15/2016

8/9/2016

5/30/2017

12/13/2017

annoying; ad • 75% first fit	aptation success rate		Copyring
0.5	11	· c 1	
Case: 7 y	ear old Hispai	nic female	 Case: 13 year old
Date 4/2/2015	Refraction -3.50-0.75x180		 NaturalVue Multifocal I OD: -4.50 OS: -4.50
	-3.00-0.732100		

► OS: -4.50
 Axial Length
OD: 26.07 mm

MiSight' 1 day

-





-5.00 DS



Philip Cheng

























	f Myopia Profile	Q 🥵 Justin	
Myopia Profile	Myopia Profile	Thomas Aller shared a link. January 19 at 7:38 AM This may hope spectral at the bat IMC, but this paper offers spece	low to Blog Q
PT	About	evidence that Atropine may control myopia progression by amplifying the	
	Discussion	response of the eye to myopic defocus. Patients often ask how atropine works and now instead of saying, "who knows?" or "it's some kind of big	
BZ	Chats	mystery," we can say that we think we know how it might work, but as to	
	Announcements	kind of big mystery." It does add to earlier findings probably by the same	
OFC	Members	group that atropine inhibits choroidal thinning in response to hyperopic defocus while not affecting choroidal thickening in response to myopic	
	Events	defocus. They make the point that since atropine likely potentiates the	B.
	Videos	effect of defocus treatments, it is highly likely that such treatments would be additive.	
	Photos	IOUS ARVO IOLIRINALS ORG	
	Files	The Effect of Atropine on Human Global Flash mfERG	
	Recommendations	Responses to Retinal Defocus IOVS ARVO Journals Safal Khanal, Philip R. K. Turnbull, Nicholas Lee, John R. Phillips; The	ALC:N
Introducing My	Search this group Q	Effect of Atropine on Human Global Hash mtEKG Responses to Retinal Defocus. Invest. Ophthalmol. Vis. Sci. 2019;60(1):218-225. doi:	
	Shortcuts	Alan Glazier, Sally Dillehay and 19 others 8 Comments 1 Share	
A clinical framework tool development and progress	OSDocs II Chicago Whiskey Festi	D Like Comment	
* Contains latest research o	oo Myopia Profile	View 6 more comments	
* Easy to use chair side info	7 Ortho-K Lens Speci 🔞	Jason Wang Nick Lee this paper seems to be really informative	
 Assists in treatment strate 	GPLI Contact Lens Exp	Like - Reply - 1w	
 Customisable patient hand 	TPG Lounge 20+	David Stephensen Thanks for sharing Thomas Aller. I'm not sure	
DOWNLOAD FREE COPY	Fellows Doing Researc	 that these observations are that definitive in terms of proof for our current optical myopia control practices, apart from 	
	Corporate Optome 20+	suggesting that the area or errect of atropine is in the peripheral retina. That fL., See More	
•	 Turner Syndrome 20+ 	Like - Reply - 1w	
	✓ See more	🗣 📵 Paul Planer replied - 3 Replies	



Strategies

- Create a brochure that summarizes in layman terms the three methods of myopia control
 - Atropine
- Orthokeratology
- Multifocal contact lenses
- Customize your health history form
- Consider setting I to 2 half days a week for myopia control and consultations, include evenings and weekends
- Consider dedicating one staff member to identify myopia control candidates and be patient care coordinator

Breakfast Start/Dismissal Recess – Gr. 4	8:10 - 8:45 8:50 - 3:17	8:10 - 8:45 8:50 - 2:08	8:10 - 8:45
Start/Dismissal Recess – Gr. 4	8:50 - 3:17	8:50 - 2:08	8-50 - 12-10
Recess - Gr. 4			8.30 = 12.19
	11:00 - 11:15	11:00 - 11:15	n/a
Recess – Gr. 5-6	11:20 - 11:35	11:20 - 11:35	n/a
Lunch – Gr. 4-6	1:00 - 1:45	1:00 - 1:45	10:40 - 11:00 (4) 11:00 - 11:20 (5-6)
Lunch – Gr. 4-6	1:00 - 1:45	1:00 - 1:45	11:00 - 11:20 (5



Take home points

- Starts with education
- Myopia is one of the strongest but modifiable risk factors in health
- Will take at least a generation to undo some of this epidemic
- \blacktriangleright Keep all kids < -6.00 and < 26.00 mm axial length